Gibson T, Grahame R
Br J Rheumatol. 1983 Nov;22(4):218-23. doi: 10.1093/rheumatology/22.4.218.
A double-blind cross-over study of cyclofenil and placebo treatments was conducted in 11 scleroderma patients. Each treatment period was for four months. A range of subjective and objective measurements failed to reveal any consistent or obvious response to cyclofenil. One patient died of his disease during active treatment. Four were withdrawn because of liver dysfunction which was attributed to cyclofenil. It remains to be seen whether treatment over longer periods will exert a clinically significant effect.
对11名硬皮病患者进行了环苯吩嗪和安慰剂治疗的双盲交叉研究。每个治疗期为四个月。一系列主观和客观测量均未显示出对环苯吩嗪有任何一致或明显的反应。一名患者在积极治疗期间死于该病。四名患者因肝功能障碍而退出，肝功能障碍归因于环苯吩嗪。长期治疗是否会产生临床显著效果还有待观察。
